News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoCellular Therapeutics, Ltd Announces Clearance of IND Application for Phase I Study of Company’s Second Vaccine Product Candidate in Recurrent GBM


7/25/2012 9:44:51 AM

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (NYSE MKT: IMUC) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC’s novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES